Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cis-Nerolidol is a naturally occurring sesquiterpene alcohol and a geometric isomer of nerolidol found in various essential oils, such as neroli and jasmine. It is currently under investigation for its potent antitumor properties, particularly in the context of bladder carcinoma. The compound exerts its effects by inducing DNA damage and endoplasmic reticulum (ER) stress. Mechanistically, it activates a signaling axis involving cyclic adenosine monophosphate (cAMP), calcium (Ca2+), and mitogen-activated protein kinase (MAPK) pathways. This activation leads to two distinct cell death pathways: an early caspase-dependent mechanism characterized by membrane blebbing and cell swelling, and a late caspase-independent mechanism involving cytoplasmic vacuolization. Beyond its oncology potential, cis-nerolidol exhibits antioxidant, antibacterial, and antiparasitic activities.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cis-nerolidol.